 Home > Biochemistry News > Biotechnology News > Target p53!

Target p53!

 Last Update: 2022-08-10
 Source: Internet
 Author: User

Tags

invitation letter meeting

phase glass needles

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

PMV Pharmaceuticals announced that it will present preliminary results of a Phase 1/2 clinical trial of its lead investigational therapy PC14586 at this year's ASCO annual meeti.

TP53, which encodes p53, is a well-known tumor suppressor gene in huma.

PC14586, developed by PMV, is a potential "first-in-class" p53 reactivator that binds to the p53 Y220C muta.

Of the 10 patients treated with higher doses of PC14586, 3 patients (30%) achieved partial responses, including patients with multiple cancer types, the ASCO abstract show.

References:

[1] PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeti.

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Targeting MDM2-p53 degradation presents a new opportunity for the development of MDM2-p53 inhibitors

02-12

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Target p53!

Related Articles

Targeting MDM2-p53 degradation presents a new opportunity for the development of MDM2-p53 inhibitors